Plasma <i>p</i> ‐tau <sub>217</sub> as a suitable biomarker for monitoring cognitive changes in Alzheimer's disease
Our findings demonstrate that tau-PET and plasma p-tau<sub>217</sub> are robust biomarkers for monitoring cognitive changes, with plasma p-tau<sub>217</sub> offering a cost-effective, scalable alternative for clinical use. Changes in amyloid-PET do not reliably reflect cognitive decline, limiting its utility as a treatment monitoring tool. Although cortical thickness correlates with cognitive changes, its application is limited by pseudoatrophy and volume loss induced by anti-amyloid antibody treatments.
Authors
- Amir Dehsarvi (ORCID: https://orcid.org/0000-0001-7116-9741)
- Anna Steward (ORCID: https://orcid.org/0000-0002-8438-3760)
- Fabian Hirsch (ORCID: https://orcid.org/0000-0002-5370-4031)
- Nicolai Franzmeier (ORCID: https://orcid.org/0000-0001-9736-2283)
- Davina Biel (ORCID: https://orcid.org/0000-0002-2597-1992)
- Sebastian N. Roemer‐Cassiano
- Zeyu Zhu
- Anna Dewenter
- Lukas Frontzkowski
- Matthias Brendel
Institutions
- German Center for Neurodegenerative Diseases (DE)
- LMU Klinikum (DE)
- Munich Cluster for Systems Neurology (DE)
- Ludwig-Maximilians-Universität München (DE)
- University of Gothenburg (SE)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_104771
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00